Evidence map›Paper›PMID 40374633›Full record

ArticleNature communications2025

G

Luca Franchini, Joseph J Porter, John D Lueck, Cesare Orlandi

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Luca FranchiniDepartment of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY, 14642, USA.ORCID http://orcid.org/0000-0002-2845-2223
Joseph J PorterDepartment of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY, 14642, USA.ORCID http://orcid.org/0000-0002-4542-0338
John D LueckDepartment of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY, 14642, USA.ORCID http://orcid.org/0000-0002-1820-711X
Cesare OrlandiDepartment of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY, 14642, USA. cesare_orlandi@urmc.rochester.edu.ORCID http://orcid.org/0000-0002-4992-9350

Funding

In vivo delivery of engineered tRNAs for suppression of nonsense mutationsR01HL153988 · NHLBI · UNIVERSITY OF ROCHESTER · PI John D. Lueck · 2021 to 2026
$3.4M
Discovery of synthetic and endogenous ligands for orphan GPCR GPR156R01DC022104 · NIDCD · UNIVERSITY OF ROCHESTER · PI Cesare Orlandi · 2024 to 2026
$2.0M
NIDCD NIH HHS R01 DC022104U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL153988U.S. Department of Health & Human Services | NIH | National Institute on Deafness and Other Communication Disorders (NIDCD) R01DC022104
6 · The paper itself

Abstract

G protein-coupled receptors (GPCRs) are key pharmacological targets, yet many remain underutilized due to unknown activation mechanisms and ligands. Orphan GPCRs, lacking identified natural ligands, are a high priority for research, as identifying their ligands will aid in understanding their functions and potential as drug targets. Most GPCRs, including orphans, couple to G

Indexed as

Biological AssayReceptors, G-Protein-CoupledAnimalsBrainHEK293 CellsHumansLigandsLigandsReceptors, G-Protein-Coupled

Identifiers

PMID40374633
PMCPMC12081699

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.